82VS
Overview
82VS is a venture studio and the investment arm of Alloy Therapeutics that builds and invests in capital-efficient, asset-focused pharmaceutical and biotechnology companies.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Ypsilon Therapeutics | Nov 2024 | Seed | Co-investor |
| Arpelos Biosciences | Mar 2024 | Seed | Co-investor |
| Cantai Therapeutics | Nov 2023 | Seed | Lead |
| Aldebaran Therapeutics | Feb 2022 | Accelerator | Lead |
| Epana Bio | Mar 2025 | Seed | Co-investor |
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is 82VS based?
82VS is headquartered in Boston, Massachusetts, United States.
When was 82VS founded?
82VS was founded in 2020.
How many portfolio companies does 82VS have?
82VS has 6 portfolio companies in Caplight's dataset.
What are some companies in 82VS's portfolio?
Portfolio companies visible on Caplight include Ypsilon Therapeutics, Arpelos Biosciences, Cantai Therapeutics, Aldebaran Therapeutics, Epana Bio.
What was 82VS's most recent investment shown here?
82VS's most recent investment in this portfolio sample was in Epana Bio in 2025.
What sectors does 82VS focus on?
82VS focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, AI, Data & Cloud Infrastructure.
What company stages does 82VS focus on?
82VS typically invests at the Early stage.